medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2013, Number S1

<< Back Next >>

Evid Med Invest Salud 2013; 6 (S1)

Relevant aspects in cancer care at the Hospital Regional de Alta Especialidad of Oaxaca, Mexico

García-Matus R, Leyva-García O, Valencia-Mijares NM, Navarro-Hernández QC, Pérez-Sánchez U

Language: Spanish
References: 15
Page: 16-19
PDF size: 346.49 Kb.


ABSTRACT

The High Specialty Regional Hospital of Oaxaca has become an opportunity to generate a model of comprehensive medical care for the treatment of complex diseases that require highly specialized medical care, evidence of this is in cancer patients. Peritoneal carcinomatosis is a common evolution of gastrointestinal tract or gynecological cancers. Currently, treatment is carried out with cytoreductive surgery and application of intraperitoneal chemotherapy with hyperthermia. The rigorous preoperative diagnostic study, strict selection criteria and surgical oncologists with experience in cytoreduction are mandatory and relevant to initiate a program of treatment of peritoneal carcinomatosis. The attention of highly complex conditions has been performed at our institution consolidating the program of peritoneal carcinomatosis, which has allowed the multidisciplinary team involved in treating these patients such as anesthesiologists, intensive care physicians, internists, rehabilitation specialists, medical oncologists, surgical oncologists and nurses, to gain expertise, making the hospital a center of reference for this type of treatment.


REFERENCES

  1. Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg. 1989; 32: 164-170.

  2. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221 (1): 29-42.

  3. Jacquet P, Sugarbaker PH. Peritoneal carcinomatosis: principles of management. Boston, USA. Kluwer Academic Publishers: 1996, 359.

  4. NCT01628380: http://clinicaltrials.gov/show/NCT01628380 consultado el 20 de noviembre de 2013

  5. NCT 00426257: http://clinicaltrials.gov/ct2/results?term=NCT+00426257&Search=Search consultado el 20 de noviembre 2013

  6. Harmon RL, Sugarbaker PH. Pronostic indicators in peritoneal carcinomtosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005; (1): 3.

  7. Esquivel J et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. An Surg Oncol. 2007; 14 (1): 128-133.

  8. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006; 243: 212-222.

  9. Pelz et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin [internet]. BMC Cancer. 2010; 10: 689. Disponible en: http://www.biomedcentral.com/1471-2407/10/689

  10. 10 Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011; 22 (10): 2250-2256.

  11. 11 Lee DH, Oh SY, Lee YR, Huh SJ, Yoon HH, Kim SH, Lee S, Lee JH, Kim Y, Kim HJ, Kwon HC. A phase II study of modified FOLFOX4 for colorectal cancer patients with peritoneal carcinomatosis. Can Res Treat. 2011; 43 (4): 225-230.

  12. 12 Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841J. Clin Oncol. 2012; 30 (3): 263-267.

  13. 13 Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH, Punt CJ. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012; 38 (7): 617-623.

  14. 14 García-Matus R. Quimioterapia intraperitoneal: técnica quirúrgica. Cancerología. 2008: 125-130.

  15. 15 García-Matus R, Hernández-Hernández CA, Leyva-García O, Vásquez-Ciriaco S, Flores-Ayala G, Navarro-Hernández Q et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: initial experience in Oaxaca, Mexico. Am Surg. 2012; 78 (9): 942-946.




2020     |     www.medigraphic.com